Compare GROV & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GROV | SER |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.1M | 42.0M |
| IPO Year | 2021 | 2024 |
| Metric | GROV | SER |
|---|---|---|
| Price | $1.05 | $2.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $1.60 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 86.9K | 62.0K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.26 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $173,716,000.00 | $130,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 132.14 |
| 52 Week Low | $0.86 | $1.22 |
| 52 Week High | $1.57 | $5.83 |
| Indicator | GROV | SER |
|---|---|---|
| Relative Strength Index (RSI) | 43.24 | 42.46 |
| Support Level | $0.86 | $1.69 |
| Resistance Level | $1.15 | $2.95 |
| Average True Range (ATR) | 0.07 | 0.20 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 40.00 | 13.33 |
Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.